Anthropic IPO filing flags ‘existential risks to humanity’ from AI as revenue hit nearly $4.6bn in 2025
AI Market Summary
Anthropic's IPO filing highlights rapid revenue growth alongside widening operating losses and extensive "existential" AI risk disclosures, which could tighten risk premiums across AI-linked equities as investors reassess regulatory, safety, and monetization uncertainty. Separately, reports of OpenAI shelving a model over safety issues reinforce near-term governance and liability overhangs. In the UK, falling gilt yields signal modest relief on fiscal-risk pricing, while AstraZeneca's $2bn oncology tie-up is idiosyncratically supportive for pharma.
Impact level
● Medium
Affected assets
NCSKANTHROPIC2USD/USDT-0.98%
AI Insight · NCSKANTHROPIC2USD/USDTAI Insight
● Neutral
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
Anthropic’s IPO prospectus warns that advanced AI could pose “catastrophic or existential risks to humanity,” as the Claude chatbot maker pursues a flotation that could value it at more than $2tn. The filing shows revenue grew 12fold in 2025 to nearly $4.6bn, while its operating loss widened to over $8bn from nearly $3bn in 2024. Separately, AstraZeneca said it will invest $2bn in Summit Therapeutics in a cancer drug collaboration. Vesuvius shares jumped almost 25% and the 10-year UK gilt yield fell 4.4 basis points to 5.385%.
